Logo image of SER

SERINA THERAPEUTICS INC. (SER) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:SER - US81751A1088 - Common Stock

4.26 USD
+0.35 (+8.95%)
Last: 11/28/2025, 8:00:30 PM
Fundamental Rating

2

Overall SER gets a fundamental rating of 2 out of 10. We evaluated SER against 533 industry peers in the Biotechnology industry. While SER seems to be doing ok healthwise, there are quite some concerns on its profitability. SER does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SER had negative earnings in the past year.
SER had a negative operating cash flow in the past year.
SER had negative earnings in each of the past 5 years.
SER had a negative operating cash flow in each of the past 5 years.
SER Yearly Net Income VS EBIT VS OCF VS FCFSER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

SER has a Return On Assets of -124.61%. This is amonst the worse of the industry: SER underperforms 80.86% of its industry peers.
The Return On Equity of SER (-618.26%) is worse than 78.61% of its industry peers.
Industry RankSector Rank
ROA -124.61%
ROE -618.26%
ROIC N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SER Yearly ROA, ROE, ROICSER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SER so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SER Yearly Profit, Operating, Gross MarginsSER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

SER does not have a ROIC to compare to the WACC, probably because it is not profitable.
SER has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SER has been reduced compared to 5 years ago.
SER has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SER Yearly Shares OutstandingSER Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SER Yearly Total Debt VS Total AssetsSER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -10.93, we must say that SER is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -10.93, SER is not doing good in the industry: 73.92% of the companies in the same industry are doing better.
There is no outstanding debt for SER. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.93
ROIC/WACCN/A
WACC8.43%
SER Yearly LT Debt VS Equity VS FCFSER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 2.24 indicates that SER has no problem at all paying its short term obligations.
SER has a Current ratio of 2.24. This is in the lower half of the industry: SER underperforms 72.80% of its industry peers.
A Quick Ratio of 2.24 indicates that SER has no problem at all paying its short term obligations.
SER has a worse Quick ratio (2.24) than 70.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.24
Quick Ratio 2.24
SER Yearly Current Assets VS Current LiabilitesSER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.97% over the past year.
The Revenue for SER has decreased by -60.56% in the past year. This is quite bad
SER shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -49.65% yearly.
EPS 1Y (TTM)88.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.45%
Revenue 1Y (TTM)-60.56%
Revenue growth 3Y-26.32%
Revenue growth 5Y-49.65%
Sales Q2Q%154.9%

3.2 Future

SER is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.59% yearly.
Based on estimates for the next years, SER will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-42.1%
EPS Next 2Y-8.67%
EPS Next 3Y3.62%
EPS Next 5Y3.59%
Revenue Next Year134.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SER Yearly Revenue VS EstimatesSER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
SER Yearly EPS VS EstimatesSER Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SER Price Earnings VS Forward Price EarningsSER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SER Per share dataSER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.67%
EPS Next 3Y3.62%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SER!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERINA THERAPEUTICS INC.

NYSEARCA:SER (11/28/2025, 8:00:30 PM)

4.26

+0.35 (+8.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-23 2026-03-23
Inst Owners4.05%
Inst Owner Change11.77%
Ins Owners18.23%
Ins Owner Change0%
Market Cap44.90M
Revenue(TTM)56.00K
Net Income(TTM)-11.14M
Analysts80
Price Target13.26 (211.27%)
Short Float %0.97%
Short Ratio1.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16%
Min EPS beat(2)-53.76%
Max EPS beat(2)21.75%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-27.71%
EPS NY rev (1m)0%
EPS NY rev (3m)-23.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 801.79
P/FCF N/A
P/OCF N/A
P/B 24.92
P/tB 24.92
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-1.79
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0.01
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -124.61%
ROE -618.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.24%
Cap/Sales 96.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.24
Quick Ratio 2.24
Altman-Z -10.93
F-Score3
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.45%
EPS Next Y-42.1%
EPS Next 2Y-8.67%
EPS Next 3Y3.62%
EPS Next 5Y3.59%
Revenue 1Y (TTM)-60.56%
Revenue growth 3Y-26.32%
Revenue growth 5Y-49.65%
Sales Q2Q%154.9%
Revenue Next Year134.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-71.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-143.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.59%
OCF growth 3YN/A
OCF growth 5YN/A

SERINA THERAPEUTICS INC. / SER FAQ

What is the fundamental rating for SER stock?

ChartMill assigns a fundamental rating of 2 / 10 to SER.


What is the valuation status for SER stock?

ChartMill assigns a valuation rating of 0 / 10 to SERINA THERAPEUTICS INC. (SER). This can be considered as Overvalued.


Can you provide the profitability details for SERINA THERAPEUTICS INC.?

SERINA THERAPEUTICS INC. (SER) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for SER stock?

The Earnings per Share (EPS) of SERINA THERAPEUTICS INC. (SER) is expected to decline by -42.1% in the next year.